They don't necessarily know any more than we do. Look at all the poor and some downright wrong broker estimates there are that cover this. As others have stated, the historical (going back 20ish years) range here has been £10-18, any breakout could deliver a nice surprise (for once ;)) |
Does Citadel have the correct take on this one? I always felt that when I ran out of other pharma ideas, this was somewhere I could safely park my pharma money. But Citadel clearly see significant downside in the not too distant future. |
Europe should be nobodies lap dog |
Blujepa will be huge for GSk-no mistake. Good to see shift away from vacines, esp HIV stuff which will become less profitable. |
Give it time !!!! ;0) |
Seriously... This share sucks! |
Markets seem to be punishing this even though GSK are mopping up shares in the background!! |
Quite big sales i would have thought for that |
Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older
· Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years
· Over half of all women experience a uUTI in their lifetime, with approximately 30% suffering from a recurrent episode
· Approval based on data from the pivotal phase III EAGLE-2 and EAGLE-3 trials |
hTTps://www.gsk.com/en-gb/media/press-releases/gsk-uk-dementia-research-institute-uk-dri-and-health-data-research-uk-hdr-uk-to-collaborate-on-first-of-its-kind-dementia-research-initiative/ |
GSK's application to expand use of Nucala (mepolizumab) for the treatment of COPD accepted for review by the European Medicines Agency
· Submission based on data from MATINEE trial, which showed a statistically significant and clinically meaningful reduction in the annualised rate of moderate/severe exacerbations with mepolizumab versus placebo
· Nucala (mepolizumab) could be the first biologic with monthly dosing for patients with COPD, if approved
· More than 40 million people in Europe live with COPD, one of the leading causes of hospitalisation and death |
I get the feeling that an institutional seller is offloading their shares at ~£15; despite the buy back the share price is pegged at this level...What do others think?? |
Abdulla
You mean relocating manufacturing in US?
Old news surely?
3rd March
Pfizer CEO says he's prepared to shift manufacturing to the U.S. amid tariff threats |
Pfizer is leaving for USA all L,S & barrel . |
anhar,Still a poor yield. But I worth keeping them now for growth. GSK should get back to £18,in time, Even eventually £20 plus. Sold out of HLN. But GSK owe Infinity in my SIPP, and 281p in my FSA, Because I have held them going back to the 1980,s |
Gary I was criticising the term "defensive" regarding capital performance as that is how it was being used. But of course it depends when you bought. For me, that performance has been pretty poor over the time held.
Also, your math is wrong on the combined yield because the value of GSK is much higher than HLN. At present my GSK is worth roughly 3x my HLN so you can't use the simple arithmetic mean to arrive at the combined yield.
Using simplified example figures, on £9,000 of GSK yielding 4% and £3,000 HLN at 1%, the combined holding is worth £12,000. The income would be GSK £360 and HLN £30, total £390.
Thus the combined yield is 390/12,000 x 100 = 3.25%, ie. much nearer to GSK because of its heavier weighting in the pair. |
ViiV releases promising phase 2 data on potential long-acting HIV drugs |
ViiV releases promising phase 2 data on potential long-acting HIV drugs |
GSK is up a couple of quid now since I was scoffed at on 14 Nov when the price was £13.59 for suggesting that an upturn was due. Still further to go. |
https://www.bbc.co.uk/news/articles/cgkmrev6z2moMay explain the drop today, in the context of a share buy back... |
Not today. Hopefully doesn't take a dump back to 13 |
anhar, GSK is 4.14%,and HLN 1.66%. Hardly good Dividend income are they. Average of 2.9% on the Money. So they are defensive, growth and not Income Stocks ! |
Defensive? I guess it depends how long you've held this crock.
For me after aeons invested and never having traded, my combined GSK/HLN holding is up just 19% over the original old GSK cost. And it's HLN that has been the main power behind the rise, not the crockpot.
However as a long term hold income investor I'm only here for the divis and pay little attention to capital flucs. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
